Monitor for signs of rare, but potentially serious or life-threatening rash, most commonly within 2-8 weeks of starting or increasing the dose. Must stop medication at first sign of rash, although this may not halt progression of rash. Monitor closely for suicidal thoughts and behavior, as well as behaviors possibly associated with suicidality (e.g., akathisia, irritability, increased agitation). FDA warning on aseptic meningitis.